Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial

2019 ◽  
Vol 33 (8) ◽  
pp. 2118-2125 ◽  
Author(s):  
Makan Cheraghpour ◽  
Hossein Imani ◽  
Shahrzad Ommi ◽  
Seyed Moayed Alavian ◽  
Elahe Karimi‐Shahrbabak ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Hepatic Enzymes ◽  
Double Blind ◽  
Nonalcoholic Fatty Liver ◽  
Inflammatory Parameters ◽  
Double Blind Clinical Trial

Polyphenol intakes and risk of impaired lipid profile, elevated hepatic enzymes and nonalcoholic fatty liver disease

2019 ◽  
Vol 49 (5) ◽  
pp. 903-910 ◽  
Author(s):  
Mehrnaz Nikkhah-Bodaghi ◽  
Matin Ghanavati ◽  
Azita Hekmatdoost
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Lipid Profile ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Separate Analysis ◽  
Protective Effects ◽  
Hepatic Enzymes ◽  
Content Type ◽  
Nonalcoholic Fatty Liver

PurposePolyphenols are plant-derived bioactive compounds with some known hepato-protective effects. The purpose of this study is to evaluate the association between polyphenol consumption and risk of nonalcoholic fatty liver disease (NAFLD) and its related conditions such as impaired lipid profile and elevated hepatic enzymes.Design/methodology/approachA total of 196 NAFLD patients and 803 controls were enrolled in this case-control study. Biochemical and anthropometric measurements as well as polyphenol consumption during the previous year were assessed.FindingsIn unadjusted model, participants who consumed the third and fourth quartiles of polyphenols intake were less likely to have NAFLD in comparison to those who consumed the first quartile [odds ratio, OR: 0.48; 95 per cent confidence interval, CI: (0.30-0.77) and OR: 0.62; 95 per cent CI: (0.40-0.96), respectively]. In separate analysis of genders, this effect was seen only in male participants [OR: 0.29; 95 per cent CI: (0.14-0.58) and OR: 0.21; 95 per cent CI (0.10-0.42), respectively], and the association remained significant after adjustment for energy, body mass index, age and smoking.Originality/valueHigher total polyphenol intake is associated with a decreased risk of NAFLD. Prospective studies are needed to confirm these results.

scholarly journals Corrigendum to “The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease”

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
John E. Lewis ◽  
Steven E. Atlas ◽  
Oscar L. Higuera ◽  
Andrea Fiallo ◽  
Ammar Rasul ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Complete Blood Count ◽  
Controlled Trial ◽  
Double Blind ◽  
Nonalcoholic Fatty Liver ◽  
Neutrophil Lymphocyte Ratio ◽  
Glutamyl Transferase

The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n = 12 RBAC and n = 11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (−3.1%; SD = 19.9; F[1, 19] = 5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1, 19] = 5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1, 19] = 12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1, 19] = 4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1, 19] = 5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD. This trial is registered with NCT02568787.

Sign in / Sign up

Export Citation Format

Share Document